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Introduction
Long after the introduction of anti-hormone therapy and anti-
HER2 therapy, treatments have again been introduced with the
new targeted and immuno-oncological therapies (CDK4/6 inhib-
itors; PI3K inhibition; anti-PD‑1/PD‑L1 antibodies; PARP inhibitors)
that are linked to a biomarker that predicts treatment efficacy. Al-
so, the first applications from the field of machine learning have
been reported, which might be of significance in this context. This
review article summarises the latest information published in the
last few months or presented at large international conferences
like ESMO 2019.
Immunotherapy
Overview
Immunotherapy with checkpoint inhibitors is becoming increas-
ingly important in oncology. For breast cancer, PD-1 and PD‑L1
inhibitors have recently been approved or are currently tested in
larger confirmatory phase III studies. The licensing situation
(FDA; USA) is shown in ▶ Fig. 1. Already, there have thus been over
5 years of clinical experience with this substance class. Combina-
tions with antibodies against CTLA4 are also licensed for other tu-
mour types. Moreover, substances against LAG-3 and B7-H3 are
at the early clinical trial stage. With regard to breast cancer, only
atezolizumab is so far licensed in combination with nab-paclitaxel
in TNBC patients whose immune cells in the tumour show PD‑L1
expression [4].
Immunohistochemical testing for PD‑L1 positivity
Some of the indications for PD-1/PD-L1 antibodies are linked with
a diagnostic test for PD‑L1 in the tumour tissue, and various im-
munohistochemical methods and algorithms are used. While
some consider the expression only in immune cells in the tumour
[1], others assess the combined expression in immune cells in the
tumour and also in tumour cells [2]. The IC (immune cell) score
was used in the Impassion130 study with atezolizumab and the
CPS (combined positive score) was used in the KEYNOTE-119,
-355 and -522 studies with pembrolizumab. ▶ Fig. 2 shows a defi-
nition of the two assessment methods and ▶ Fig. 3 shows an ex-
ample of CPS. There is little experience comparing different anti-
bodies and determination methods. Such a comparison with the
antibodies SP142 (IC ≥ 1%), SP263 (IC ≥ 1%) and 22C3 (CPS ≥ 1)
ABSTRACT
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gous recombination, or patients with tumours that show an
abnormality in global tests of homologous recombination de-
ficiencies (HRD tests). The question of whether a PARP inhib-
itor can be given and with which chemotherapy combination
partners is currently being investigated in both breast and
ovarian cancer. While the data on improved overall survival
are being consolidated for the CDK4/6 inhibitors, knowledge
of molecular changes during the therapy and during progres-
sion on the therapy is growing. Both the accumulation of PI3K
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ning subsequent therapies. This review article summarises
these recent developments in breast cancer and in part also
in ovarian cancer.
ZUSAMMENFASSUNG
Im Rahmen von aktuell laufenden Studien werden in naher
Zukunft wichtige translationale Fragestellungen von kli-
nischer Relevanz geklärt werden. Zum einen muss die Rolle
der PD‑L1-Expression, nachdem sie für die Indikationsstellung
für Atezolizumab in der 1. Therapielinie bei Patientinnen mit
einem metastasierten triple-negativen Mammakarzinom
(TNBC) von Relevanz ist, weiter geklärt werden. In einer neo-
adjuvanten Studie beim TNBC mit Pembrolizumab konnte
kein Zusammenhang zwischen Wirksamkeit und PD‑L1-Ex-
pression gefunden werden. Sowohl mit als auch ohne Expres-
sion war die pCR höher, wenn Pembrolizumab zur Chemothe-
rapie hinzugefügt wurde. Des Weiteren wird für die bei Keim-
bahnmutation von BRCA1/2 zugelassenen PARP-Inhibitoren
nach weiteren Patientengruppen gesucht, in denen eine Wirk-
samkeit besteht. Dieses sind z.B. Patientinnen mit Mutatio-
nen in anderen Genen, die an der homologen Rekombination
beteiligt sind, oder Patientinnen mit Tumoren, die bei globa-
len Tests zu homologen Rekombinationsdefizienzen (HRD-
Tests) eine Auffälligkeit zeigen. Auch die Frage, ob und mit
welchen Chemotherapie-Kombinationspartnern eine PARP-
Inhibition zusammen gegeben werden kann, wird aktuell so-
wohl beim Mamma- als auch beim Ovarialkarzinom unter-
sucht. Während sich die Daten zum verbesserten Gesamt-
überleben bei den CDK4/6-Inhibitoren konsolidieren, wächst
auch das Wissen um molekulare Veränderungen unter der
Therapie und bei der Progression unter der Therapie. Sowohl
die Anhäufung von PI3K-Mutationen als auch PTEN-Verände-
rungen könnten bei der Planung von Folgetherapien eine Rol-
le spielen. Diese Übersichtsarbeit fasst diese aktuellen Ent-
wicklungen beim Mammakarzinom und teilweise auch beim
Ovarialkarzinom zusammen.
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was carried out recently in the Impassion130 study [3]. All test
methods were able to identify populations in which atezolizumab
and nab-paclitaxel were more effective with regard to overall sur-
vival than monotherapy with nab-paclitaxel (SP142 HR: 0.74; 95%
CI: 0.54–1.01/22C3 HR: 0.78; 95% CI: 0.62–0.99/SP263 HR: 0.75;
95% CI: 0.59–0.96) [3].
KEYNOTE-119
With regard to the treatment of TNBC patients in the first line set-
ting with atezolizumab and nab-paclitaxel, it has already been
shown that PD‑L1 positivity with the IC score is necessary for effi-
cacy, while no benefit was shown for atezolizumab in tumours
with a negative IC score [4]. Knowledge of these data and experi-
ence with other diseases raise the questions of
Melanoma*
Diagnostic
antibody
for IHC
22C3,
Dako
Melanoma*
28-8,
Dako
Urothelial Ca* **,
SP142,
Ventana
MCC*
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( for urothelial Ca)
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IA
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: 03/2017
( for MCC)
Avelumab
IA
IA for urothelial Ca
: 05/2017
( )
Durvalumab
▶ Fig. 1 Approval status (FDA, USA, status quo June 2019) of selected therapeutic PD-1/PD-L1 antibodies relevant for breast cancer (IA: initial ap-
proval [FDA, USA], IHC: immunohistochemistry, NSCLC: non-small cell lung cancer, MSI: microsatellite instability, HCC: hepatocellular carcinoma,
PMBCL: primary mediastinal large B cell lymphoma, SCLC: small cell lung cancer, TNBC: triple negative breast cancer, RCC: renal cell cancer,
* Tumour for which initial approval was granted, ** indication linked to PD‑L1-testing). For all indications only the cancer entity is mentioned.
Other criteria are not mentioned (e.g. therapy line or other diesease conditions). For exact information please refer to the official prescribing
informations.
Immune cell score
(IC score)
IC =
CPS =
× 100
× 100
Intratumour area with positive MIC
Number of positive MIC + number of positive tumour cells
Tumour area
Number of tumour cells
Combined positive score
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Cut-off in TNBC
(atezolizumab): 1%≥
Cut-off reported in
pembrolizumab studies:
1%/ /≥ ≥ ≥10% 20%
▶ Fig. 2 Definitions of PD‑L1 stains that were used for clinical approval studies [1,2] (MIC: mononuclear inflammatory cells).
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1. the efficacy of other PD-1/PD-L1 antibodies,
2. the efficacy of monotherapy,
3. other combination partners and
4. their effectiveness in later treatment lines.
In this context, the KEYNOTE-119 study shows important results.
Patients with advanced triple-negative breast cancer who had al-
ready concluded at least one treatment line in the metastatic sit-
uation took part in this study. Following randomisation, the pa-
tients were treated either with monotherapy with the anti-PD‑1
antibody pembrolizumab or chemotherapy (physicianʼs choice:
capecitabine, vinorelbine, eribulin or gemcitabine). Treatment
did not depend on PD‑L1 expression, but the CPS score was a
stratification factor. The primary study aims were differences in
overall survival in patients with a CPS score ≥ 10, a CPS score > 0
and, if these study aims were reached, in the overall group also.
Overall, the study was negative, but a clear trend could be seen
that pembrolizumab was superior to chemotherapy with increas-
ing PD‑L1 expression. The hazard ratios are given in ▶ Table 1 and
the overall survival with pembrolizumab or chemotherapy de-
pending on the CPS score is shown in ▶ Fig. 4. It remains to be dis-
cussed whether PD‑L1 expression in highly pre-treated patients
can be used as a selection criterion for therapy with pembrolizu-
mab. In view of the lack of standard therapies in advanced therapy
lines, this could be an option.
KEYNOTE-522
Since anti-PD‑L1/PD-1 therapies have become established for pa-
tients with advanced breast cancer, it makes sense to test this
treatment in patients with early breast cancer also. Tumours in
the treatment-naive situation should theoretically have a lower
chance of developing an immune escape phenomenon because
of the lack of therapeutic exposure. A certain superior efficacy in
the neoadjuvant treatment situation was already shown in the Ge-
par-Nuevo study, although the study result was not statistically
significant [5]. In the KEYNOTE-522 study, the addition of a check-
point inhibitor has now been evaluated in a large neoadjuvant
phase III study [6]. Patients with a triple-negative tumour were in-
cluded in this study if neoadjuvant chemotherapy was indicated.
The patients were treated with platinum-containing chemother-
apy or platinum-containing chemotherapy with the addition of
pembrolizumab. The patients were not preselected according to
criteria that consider the expression of PD-1 or PD‑L1. A total of
1174 patients were randomised in a 2 :1 ratio. It was shown that
the pathological complete remission rate (pCR rate) was in-
creased from 51.2 to 64.8% by the addition of pembrolizumab
[6]. This difference was statistically significant (p = 0.00055). In-
terestingly, the effect was not dependent on the CPS score. In pa-
tients without PD‑L1 expression, pCR was shown in 30.3% of cases
with chemotherapy, while pCR was seen in 45.3% of cases with
chemotherapy and pembrolizumab. With a CPS ≥ 1 the pCR rates
Tumour
PD-L1 stained tumour cell
PD-L1 unstained tumour cell
PD-L1 stained mononuclear
inflammatory cell (MIC)
PD-L1 unstained mononuclear
inflammatory cell (MIC)
90% unstained
10% stained
▶ Fig. 3 Example of CPS (combined positive score) assessment. There are approximately 100 tumour cells in the area which is stained for PD‑L1. In
this area there are approximately 80 stained cells (tumour cells and mononuclear cells). There are therefore approximately 8% positive cells in the
entire tumour, which corresponds to a CPS of 8 (example taken from: [2]) (© Agilent Technologies, Inc. Reproduced with Permission, Courtesy of
Agilent Technologies, Inc.). [rerif]
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were 54.9% (chemotherapy) and 68.9% (chemotherapy + pem-
brolizumab).
With regard to event-free survival (EFS), patients on pembroli-
zumab had a lower risk for a disease event (HR = 0.63; 95% CI:
0.43–0.93) [6]. However, statistical significance was not reached
formally for this interim analysis. The follow-up for this analysis
was extremely short and few events occurred. Future interim anal-
yses must therefore be awaited.
Hormone Resistance
Update on CDK4/6 inhibitors –
growing data on overall survival
Combined treatments that aim to overcome mechanisms of pri-
mary or secondary endocrine resistance have been investigated
for a few years. Everolimus was one of the first substances that
showed a marked benefit with regard to progression-free survival
[7] but which did not extend to overall survival [8]. The CDK4/6
inhibitors (CDK4/6i), in combination with anti-endocrine therapy,
uniformly showed an improvement in progression-free survival
with hazard ratios between 0.5 and 0.6 (summarised in [9]). Some
of these studies have already been analysed with regard to overall
survival. ▶ Table 2 gives an overview of PFS and OS data.
With regard to overall survival also, similarity can be identified
between the studies. As with all substance classes in which no di-
rect comparison has been made between the substances, it is dif-
ficult to draw conclusions on whether one or the other substance
has greater effectiveness. It is also difficult to assess minor differ-
ences with regard to the side effect profile. Three studies to date
have shown a statistically significant survival advantage (MONA-
LEESA-3, MONALEESA-7, MONARCH-2) [10–12], while this aim
was shown only with a p value of 0.09 in the PALOMA-3 study,
which showed however a a similar effect size [13]. The results of
the MONARCH-3, PALOMA-2 and MONALEESA-2 studies are still
pending and will surely be able to provide additional information
about this substance class.
While it has now been shown that overall survival is better with
combined therapy consisting of CDK4/6i+ET than with monother-
apy, the question of whether this is a long-term effect has not yet
▶ Table 1 Comparison of overall survival between pembrolizumab and chemotherapy in the KEYNOTE-119 study according to CPS subgroups
(from [45]).
CPS score Number of patients
Pembro vs. chemo
median OS
Pembro
median OS
Chemo
HR (95% CI)
Total ITT population 312 vs. 310  9.9 (8.3–11.4) 10.8 (9.1–12.6) 0.97 (0.92–1.15)
CPS ≥ 1 203 vs. 202 10.7 (9.3–12.5) 10.2 (7.9–12.6) 0.86 (0.69–1.06)
CPS ≥ 10  96 vs. 98 12.7 (9.9–16.3) 11.6 (8.3–13.7) 0.78 (0.57–1.06)
CPS ≥ 20  57 vs. 52 14.9 (10.7–19.8) 12.5 (7.3–15.4) 0.58 (0.38–0.88)
O
S
(%
)
O
S
(%
)
Pembrolizumab monotherapy Chemotherapy
Time (months) Time (months)
a b
100
90
80
70
60
50
40
30
20
10
0
100
90
80
70
60
50
40
30
20
10
0
40 4030 3020 2010 100 0
All patients All patients
CPS 1≥ CPS 1≥
CPS 10≥ CPS 10≥
CPS 20≥ CPS 20≥
▶ Fig. 4 Overall survival according to CPS score in the KEYNOTE-119 study separately for patients treated with pembrolizumab (a) and patients
treated with chemotherapy (b). (modified from [45]).
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been answered. At the present time, it can only be concluded that
fewer deaths occurred during the (short) follow-up period of the
reported study in the stated circumstances.
Biomarkers and CDK4/6 inhibitors
Data that analysed mutation frequencies before the start of treat-
ment and at the time of progression have already been published
in the PALOMA-3 study. This showed that a PIK3CA mutation,
which was not detectable at the start of treatment, was found in
8.2% of patients at the end of treatment [14]. This is important
especially because it was shown in the SOLAR-1 study that combi-
nation with the PIK3CA inhibitor alpelisib and fulvestrant achieved
improved progression-free survival in patients with a PIK3CA mu-
tation compared with treatment with fulvestrant alone [15]. A
small subgroup analysis suggests that this effect is independent
of prior treatment with a CDK4/6 inhibitor [15]. Large studies of
treatment with alpelisib after a CDK4/6 inhibitor are still recruiting
and will deliver extensive data on the efficacy of alpelisib after
CDK4/6 inhibitor therapy (BYLIEVE study).
The data on PIK3CA mutation accumulation from the PALOMA-
3 study show that planning of therapy sequences in future may be
linked to targeted molecular diagnostics. In another small study of
letrozole and ribociclib (n = 5) with paired tumour samples before
treatment and on progression on therapy, it was shown that the
loss of expression can also have a role through a loss of gene cop-
ies [16]. Four of these 5 patients had a loss of RB or PTEN [16].
Even with the small number of patients, these results are interest-
ing because they were supported by preclinical experiments and it
was already implied that a loss of PTEN could be associated with
resistance to PI3K inhibitor therapy [17]. PTEN loss is of particular
interest in the context of new treatments because the tumour
suppressor PTEN is a counter-regulator of the Akt/PI3K signalling
pathway and loss suggests lack of counter-regulation of this sig-
nalling pathway.
The interaction between PIK3 and PTEN appears, however, to
be more complex in that the different subunits of PIK3 play a dif-
ferent role in PTEN-deficient breast cancer [18]. Future studies will
clarify whether PI3K inhibitor therapy has a part to play in such pa-
tients.
It should be noted that loss of gene copies of RB and/or PTEN
was also investigated in the PALOMA-3 study but was not found
there [14].
PARP Inhibition
Another treatment that was introduced based on a biomarker is
treatment with a PARP inhibitor. An improvement in PFS was
shown in large phase III studies for patients with HER2-negative,
advanced breast cancer and a germline mutation in BRCA1 or
BRCA2 (OlympiAD study and EMBRACA study) for the two PARP
inhibitors olaparib and talazoparib compared with chemotherapy
[19,20]. Patients on olaparib, who had not received any chemo-
therapy for their metastatic disease, even showed an overall sur-
vival advantage. It was also shown that monotherapy with the tar-
geted PARP inhibitor leads to an improvement in quality of life
compared with chemotherapy [21,22].
PARP inhibitors in combination with platinum in
patients with breast cancer and BRCA1/2 mutation
While the OlympiAD and EMBRACA studies compared a PARP in-
hibitor and non-platinum-containing mono-chemotherapy, the
question arises in patients with a germline mutation in BRCA1 or
BRCA2 of whether platinum-containing chemotherapy can
achieve similar effects. It is known that a BRCA1/2 mutation is a
predictor for the particular efficacy of platinum therapy. The TNT
study showed this in a comparison with therapy with a taxane
[23]. The high efficacy of platinum chemotherapy in patients with
a BRCA1/2 mutation was also shown in the neoadjuvant studies
[24–26]. Consequently, the question is whether PARP inhibitor
therapy plays a part in patients with a BRCA1/2 mutation in addi-
tion to or compared with treatment with platinum-containing
chemotherapy. In the neoadjuvant situation, it has already been
shown in the GeparOLA study, conducted in patients with a
BRCA1/2 mutation (germline or somatic) or confirmed homolo-
gous recombination deficiency (HRD), that olaparib/taxane fol-
lowed by anthracycline-containing chemotherapy leads to a simi-
lar or slightly improved nominal pCR rate compared with carbo-
platin/taxane followed by the anthracycline-containing chemo-
therapy [27]. In the recently presented BROCADE-3 study, this
topic was investigated with the PARP inhibitor veliparib in the
metastatic treatment situation [28]. This study included patients
with advanced HER2-negative breast cancer who had a germline
mutation in BRCA1/2, had not received more than 2 chemothera-
pies in the advanced situation and had received a maximum of
one treatment line with platinum-containing chemotherapy, after
which no rapid progress (≤ 12 months) was permitted. 513 pa-
tients in total were included in the study, randomised 2 :1 in fa-
▶ Table 2 Progression-free survival and overall survival for the reported phase III studies with a CDK4/6 inhibitor (date of PFS and OS: month the
database closed for the first analysis).
Study n Recruitment PFS date OS date PFS (95% CI) OS (95% CI) Reference
PALOMA-3 521 10/2013–08/2014 12/2014 04/2018 0.42 (0.32–0.56) 0.81 (0.64–1.03) [13,46]
MONALEESA-7 672 12/2014–08/2018 08/2017 11/2018 0.55 (0.44–0.69) 0.71 (0.54–0.95) [12,47]
MONALEESA-3 726 06/2015–06/2016 11/2017 06/2016 0.59 (0.48–0.73) 0.72 (0.57–0.92) [11,48]
MONARCH-2 669 08/2014–12/2015 02/2017 06/2019 0.55 (0.45–0.68) 0.76 (0.61–0.95) [10,49]
PFS: progression-free survival, OS: overall survival, CI: confidence interval
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vour of the PARP inhibitors; one arm received veliparib + carbopla-
tin + paclitaxel and the other arm was given only carboplatin +
paclitaxel. With regard to the primary endpoint of PFS, a statisti-
cally significant benefit was reported with a HR of 0.70 (95% CI:
0.57–0.88) [28]. This effect did not extend to overall survival in
the early analysis [28]. With regard to side effects, more grade
3–4 thrombopenia (40 vs. 28%) and more anaemia (all grades,
80 vs. 70%) was seen with veliparib + chemotherapy. The other
side effects were similar between the two groups, with a slightly
higher general side effect rate in the veliparib arm [28]. Compara-
ble data are not available for the other PARP inhibitors although
prior therapy with platinum-containing chemotherapy was per-
mitted in the studies of olaparib and talazoparib, as in the BRO-
CADE-3 study [19, 20].
PARP inhibitors in the primary treatment
of ovarian cancer
In ovarian cancer, clear benefits were shown in three recently re-
ported studies for patients who were treated with a PARP inhibitor
as maintenance therapy after primary diagnosis.
Patients with high-grade ovarian cancer/fallopian tube cancer/
peritoneal cancer stage III or IV were enrolled in the PAOLA-1
study and treated either with bevacizumab as maintenance
monotherapy or with a combination of olaparib and bevacizumab
after platinum- and taxane-containing chemotherapy. The study
showed a benefit overall for the combined arm with a HR of 0.59
(95% CI: 0.49–0.72). The effect appeared to be much more prom-
inent in the group of patients with a BRCA mutation (HR = 0.31;
95% CI: 0.20–0.47) than in patients without BRCA mutation
(HR = 0.71; 95% CI: 0.58–0.88) [29]. It was already suspected for
breast cancer that a BRCAmutation interacts with angiogenesis: in
the GeparQuinto study, a pCR rate of 61.5% was achieved in neo-
adjuvant treatment with a combination of chemotherapy and
bevacizumab [30].
The PRIMA study, in which treatment with niraparib was com-
pared with placebo after the initial chemotherapy, investigated a
similar question to the PAOLA-1 study. Here, too, a benefit in the
overall population in favour of the PARP inhibitor was demonstrat-
ed with a HR of 0.62 (95% CI: 0.5–0.76). In the PRIMA study, too,
this effect was more apparent in patients with a homologous
recombination defect (HRD) based on a BRCA1/2 mutation
(HR = 0.40, 95% CI: 0.27–0.62), while the HR was 0.50 (95% CI:
0.31–0.83) in patients with the HRD without BRCA1/2 mutation.
In patients without the HR defect, the HR was 0.68 (95% CI: 0.49–
0.94) [31].
The VELIA study, was also conducted with veliparib in the pri-
mary treatment of ovarian cancer [32]. In this three-arm study,
as in PRIMA, no maintenance treatment with bevacizumab was
given. However, the PARP inhibitor was combined with chemo-
therapy. The patients therefore received either chemotherapy
with carboplatin and paclitaxel or this chemotherapy with velipar-
ib or, in the third arm, the combination of chemotherapy + velipar-
ib, followed by maintenance therapy with veliparib. The veliparib
arm without maintenance therapy did not show any improvement
compared with the chemotherapy arm, while the veliparib arm
with subsequent veliparib maintenance therapy showed a benefit
in the overall population with a HR of 0.68 (95% CI: 0.56–0.83). In
this study, too, the effect was more obvious in the group of pa-
tients who had a mutation in BRCA1 or BRCA2 (HR = 0.44; 95% CI:
0.28–0.68) [32].
Overall, it can be confirmed that PARP inhibitor therapy repre-
sents clear progress for patients with ovarian cancer and will rap-
idly become part of clinical practice.
Biosimilars
Is trastuzumab the same as trastuzumab?
Development of a range of biosimilars became possible with the
expiry of the patent for the reference trastuzumab. Because of
the biological production process, biosimilars are not completely
identical to the reference product but the approval process re-
quires that the quality of the product is comparable to that of
the reference product, and likewise the efficacy and side effects.
In the comparative studies, however, major differences between
the reference trastuzumab and the biosimilar were noted in a
few of these studies (summarised in [33]). In the case of SB3, this
appeared to be the consequence of a reduced efficacy of the ref-
erence trastuzumab.
In the neoadjuvant study, treatment with the reference tras-
tuzumab and chemotherapy was compared with treatment with
chemotherapy and the SB3 trastuzumab in HER2-positive pa-
tients. The pCR rate with SB3 that was nearly 10% higher than
with the reference trastuzumab [34,35]. Differences were also
found in recurrence-free survival and overall survival. Events in
the form of recurrence (HR = 0.47; 95% CI: 0.26–0.87) and overall
survival (HR = 0.37; 95% CI: 0.13–1.04) occurred markedly more
seldom in the SB3 treatment arm [36].
In investigations regarding antibody-dependent cellular cyto-
toxicity (ADCC), which plays a part in the antibody-mediated ac-
tion of the natural killer cells on the tumour cells, it was found that
certain production lots of the reference trastuzumab appeared to
suggest reduced ADCC activity (relative ADCC activity, relative
FcγRIIIa binding activity) [37].
When the study was analysed separately according to the
groups SB3, reference trastuzumab with normal ADCC character-
istics and reference trastuzumab with compromised ADCC char-
acteristics, it was seen that only the group with the reference tras-
tuzumab and compromised ADCC showed clinically visible poorer
prognosis with an over five-fold increased risk for recurrence com-
pared with the non-compromised reference trastuzumab
(HR = 5.31; 95% CI: 1.74–16.25) [36]. ▶ Fig. 5 shows the corre-
sponding Kaplan-Meier curves.
These data show that large differences in efficacy, hitherto ap-
parently unidentified, can occur in the production of monoclonal
antibodies, which are very probably of clinical relevance.
Big Data and Digitisation of Medicine
Technologies that investigate large amounts of data with machine
learning or deep learning methods are being used and imple-
mented ever increasingly in medicine [38]. Applications, some of
which are already under development, could thus have a direct in-
fluence on clinical practice in the near future.
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Digital pathology and machine learning
One of the main fields of research is processing of digital image
data, which can be important especially for radiological and histo-
pathological images. In an article that appeared recently, an at-
tempt was made to establish algorithms with machine learning
that predict from the histopathological appearance whether a tu-
mour has microsatellite instability (MSI).
Microsatellite instability is the result of defective mismatch re-
pair mechanisms in DNA repair, which affects the mutation rate in
the entire genome, but especially in short tandem repeats (micro-
satellites). MSI is usually determined by immunohistochemistry
for the expression of the 4 mismatch repair genes MLH1, MSH2,
MSH6 and PMS2 [39]. A loss of expression is generally found with
a mutation. This condition is often found in colon cancer and en-
dometrial cancer.
It was shown in a recently published article how this prediction
can also be made with haematoxylin-eosin staining by means of
deep learning [40]. The AUC in a validation cohort of 378 patients
with colorectal carcinoma was 0.84. Such methods are also con-
ceivable for other tumour types, such as ovarian cancer or cervical
cancer.
Support of clinical decision-making
Another area of research is the implementation of decision-mak-
ing algorithms in routine clinical practice or tumour boards. Clini-
cal decision-making could benefit in many ways from a big data or
machine learning approach. On the one hand, systematic analysis
of patient data including treatment data and outcome data (prog-
nosis and quality of life) offers a large opportunity for using the
data recorded in routine clinical practice for modern machine
learning analysis and so make suggestions that will result in better
quality of life or prognosis for the individual patient. On the other
hand, decision-making could be improved by avoiding error. Er-
rors can occur both in the interpretation of findings and in the
compilation and presentation of findings, which lead to sub-opti-
mal decisions. Digitisation and plausibility checking at this level
could help to avoid decision errors [41]. In the PRAEGNANT net-
work in Germany [42], machine learning methods, for example,
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are used to try to optimise treatment decisions [43,44]. Useful
predictions of the optimal clinical procedure have already been
achieved by means of encoding with recurrent neuronal networks
and what is known as tensor decoding [43,44].
The extent to which decision support before, during or after
real decision-making can be integrated in routine clinical practice
remains to be seen. Appropriate studies must be conducted that
should integrate both doctors and patients.
Prospects
With the new treatments, atezolizumab, the PARP inhibitors in
breast cancer and soon the PI3K inhibitor alpelisib also, new treat-
ments have been introduced that are associated with a biomarker
that predicts the efficacy of these therapies. Implementation of
these tests will be just as demanding as extending the scientific
understanding of these markers. For example, atezolizumab ther-
apy in the metastatic situation is linked to PD‑L1 positivity of the
immune cells, while in the neoadjuvant setting, pembrolizumab
increased pCR rates independent of PD‑L1 expression. In the far
advanced treatment situation, however, pembrolizumab efficacy
appeared to correlate with PD‑L1 expression.
These examples show that simultaneously with the introduc-
tion of new predictive molecular tests into routine clinical prac-
tice, assistance in interpreting and assessing the relevance of the
test results must be provided to therapists.
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